5315992026-07-012026-09-305315992026-09-305315992026-03-315315992026-04-012026-09-305315992026-07-012026-09-30in-capmkt:OtherExpenses1Member5315992026-04-012026-09-30in-capmkt:OtherExpenses1Member5315992026-09-30OtherNoncurrentFinancialAssetsDomain15315992026-09-30OtherNoncurrentAssetsDomain15315992026-09-30OtherCurrentFinancialAssetsDomain15315992026-09-30OtherCurrentAssetsDomain15315992026-09-30OtherNoncurrentLiabilitiesDomain15315992026-09-30OtherCurrentFinancialLiabilitiesDomain15315992026-09-30OtherCurrentLiabilitiesDomain15315992026-07-012026-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15315992026-04-012026-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15315992026-07-012026-09-30AuditorDomain1iso4217:INRiso4217:INRxbrli:shares531599FDCNOTLISTEDINE258B01022FDC LIMITEDMain BoardEquity2026-04-012027-03-312026-10-272026-10-21INRLakhsQuarterlySecond quarterSingle segmentPharmaceutical2026-10-2712:30:002026-10-2715:45:00trueCash Flow IndirectDeclaration of unmodified opinion2026-07-012026-09-30UnauditedConsolidated57214000001794000005900800000139940000029910000015290000013428000008400000159800000188430000052467000006541000000654100000165500000-20000001635000000490600000000049060000096000005002000005002000000500200000016280000013.013.01003.013.01Notes: <br /> <br /> 1. The above unaudited consolidated financial results which are published in accordance with Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’) for the quarter and six months ended September 30, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the Parent Company at their meeting held on October 27, 2026. The Statutory Auditors have carried out a limited review of the above results and have expressed an unmodified review conclusion. <br /> <br /> 2. The Parent Company recognized a fair value loss of Rs. 232 lakhs under Other Expenses in the quarter ended September 30, 2026 (Rs. 143 lakhs in quarter ended September 30, 2025) in accordance with Ind AS 109 (Financial Instruments). However, for the period ended September 30, 2026, a net fair value gain of Rs. 1,608 lakhs (Rs. 1,905 lakhs for the period ended September 30, 2025) was recorded under Other Income. Due to this treatment, the quarterly numbers may not be directly additive to the year-to-date (YTD) numbers, as fair value changes are recognized based on market conditions prevailing at different reporting dates. <br /> <br /> 3. During the previous year, the Parent Company recognised an incremental employee benefit obligation of Rs. 2,079 lakhs based on an actuarial valuation in accordance with Ind AS 19 – ‘Employee Benefits‘. The impact was disclosed as an exceptional item in the financial statements for the year ended March 31, 2026, considering its non-recurring nature arising from a regulatory change. The Parent Company continues to monitor further notifications and clarifications issued by the Government and will account for any consequential impact, if required, in the period of such developments. <br /> <br /> 4. The Board of directors, at its meeting held on October 27, 2026 have approved a proposal of the Company to buy-back its 24,00,000 fully paid-up equity shares at a price of Rs. 500 per equity shares from all the eligible equity shareholders of the Company on proportionate basis through the "Tender offer" route in accordance with SEBI (Buy-Back of securities) Regulation, 2018. <br /> <br /> 5. The Group has only one segment of activity namely “Pharmaceuticals”. <br /> <br /> 6. The above results are also available on the website of the Parent Company i.e. www.fdcindia.com and on the website of the Stock Exchanges i.e. www.nseindia.com and www.bseindia.com. <br /> 2026-04-012026-09-30UnauditedConsolidated123983000006328000001303110000028444000005139000006295000002694400000167000003111000003620000000106300000002401100000024011000005633000002230000058560000001815500000000018155000001960000018351000001835100000018351000000162800000111.1511.150011.1511.15Other Expenses1884300000Other Expenses362000000010337400000163390000005130000006296200000370000026690000065668000001197600000197870000003017600000574850000015362000003621000001102000008900000853000007851200000110110000011969900000317569000001628000002652630000026689100000266891000000031950000032630000085300000731100000021780000022889000002506700000112640000036331000001199000003644000002193000004336700000506780000031756900000Other financial assets266900000Other non-current assets1197600000Other current financial assets85300000Other current assets1101100000Other non-current liabilities85300000Other current financial liabilities1126400000Other current liabilities11990000016700000533300000-279000000-17670000000-20210000004542000000816000000311100000000007200000000-160800000032400000390000000872900000327400000000-3855000003759000000251260000000000000208000001553300000000000000004670300000614940000000000400100000017800000-259370000000000000003320000050000000-9900000-43600000-1247000000-124700000486800000362100000Amount of items that will not be reclassified to profit and loss700000700000Amount of items that will not be reclassified to profit and loss240000024000000200000-8900000-17400000960000019600000UnauditedtrueBSR & Co LLPtrue2028-07-31